crtc-1 Antibody

Basic Research Questions

How to validate CRTC1 antibody specificity across experimental applications?

• Perform knockdown/knockout controls using siRNA or CRISPR-Cas9 in target cell lines, comparing signal intensity between treated and untreated groups .

• Use isoform-specific controls: CRTC1 has 3 isoforms (67 kDa, 68 kDa, 62 kDa). Validate using lysates from cells overexpressing individual isoforms .

• Multi-platform validation: Confirm antibody performance in parallel assays (e.g., Western blot vs. immunohistochemistry) using standardized positive controls like mouse brain tissue .

What are optimal conditions for CRTC1 detection in activity-dependent studies?

• Stimulation protocols: Use 50 μM forskolin + 30 mM KCl for 15–30 min to induce CRTC1 dephosphorylation and nuclear translocation in neurons .

• Lysis buffer: Include phosphatase inhibitors (e.g., 1 mM NaF + 1 mM Na3VO4) to preserve phosphorylation status .

• Dilution optimization:

How to resolve discrepancies in detecting CRTC1 isoforms?

• Post-translational modifications: Phosphorylation increases apparent MW (75–80 kDa). Treat lysates with λ-phosphatase to collapse bands to 68 kDa .

• Gel system: Use 4–12% Bis-Tris gels with MOPS buffer for improved separation of 62/67/68 kDa isoforms .

• Antibody epitope mapping: Antibodies targeting N-terminal residues (e.g., Proteintech 10441-1-AP) detect all isoforms, while C-terminal antibodies may miss truncated variants .

Advanced Research Questions

How to design co-immunoprecipitation experiments for CRTC1-CREB/AP-1 complexes?

• Crosslinker choice: Use 1% formaldehyde for 10 min to capture transient activity-dependent interactions .

• Buffer composition:

• Validation: Include reciprocal IPs (anti-CREB → check CRTC1; anti-CRTC1 → check c-Jun) .

What strategies identify CRTC1 functional domains in transcriptional regulation?

• CRISPR-Cas9 domain editing:

  • Sec31-binding domain: Mutate residues 189–202 to disrupt ER-Golgi trafficking .

  • CREB-binding domain (CBD): Alter residues 415–428 to block transcriptional activation .

• Functional readouts:

  • Trafficking: GFP::SBP-1 nuclear accumulation assay .

  • Transcription: CREp::GFP reporter in neurons .

How to reconcile opposing roles of CRTC1 in neuroprotection vs oncogenesis?

• Context-dependent analysis:

• Pathway inhibition tests: In cancer models, combine CRTC1 siRNA with AP-1 inhibitors (e.g., T-5224) to assess functional overlap .

What methods improve CRTC1 antibody performance in lifespan studies?

• Temporal expression control: Use single-copy transgenes with endogenous promoters (e.g., crtc-1p::CRTC1 in C. elegans) to avoid overexpression artifacts .

• Strain validation:

  • Outcross CRISPR lines ≥6 times .

  • Confirm rescue of both trafficking (SBP-1) and transcriptional (CREp::GFP) phenotypes .

How to address cross-species reactivity limitations?

• Epitope conservation analysis:

• Alternative approaches: For low-homology species, use HA/FLAG-tagged constructs paired with anti-tag antibodies .